The Patient Definition has always been the simplest form to determine if a patient is eligible to receive 340B priced medications. PharmaSEE allows covered entities to ensure that the HRSA guided 3-part test is accurately and consistently applied. This information will be certified as true and accurate.

Diversion is notorious in the 340B world. Man hours are spent tracking inventory purchases through invoices to contract pharmacy dispensing reports. Because this task is so tedious, many covered entities do little to track where their purchases are going. Through PharmaSEE, we will provide you with the data to resolve potential issues with the contract pharmacy, quickly and continuously.

PharmaSEE’s dashboards will enable manufacturers to get granular pill-to-patient. We will provide granularity from your loading dock to the patient’s pocket and every step in between. Covered Entities will certify and report the information on eligibility of their patient base receiving 340B medications further reducing FWA through diversion. Chargebacks due to ineligibility can be diagnosed on a continuous basis.

To be enrolled and eligible for the HRSA sponsored 340B program there are continuous Program Requirements that must be kept current. PharmaSEE will work with you and your EHR to store and present the data in an auditable and compliant format for any outside party auditor. It is important to remember the benefits you receive from the 340B program can be refunded to the Manufacturers of the discount obtained due to poor records or ineligible patients.

On top of providing Drug Traceability and ensuring that our partner Covered Entities are compliant with HRSA. PharmaSEE will alert you when each NDC sale price is greater than the 340B Ceiling price, thereby saving time and money responding to desk audits. With a click of a button, you’ll have access to whom and what you owe for the overage.

Through the use of EDI and through an API structure, our AI will continuously match pricing files from Manufacturers through to the Patients to ensure consistency. Real-time reporting will reduce lag time in chargebacks and improve efficiencies across each line in the supply chain.

The proliferation of abuse in the proceeds of 340B, purchasing, and diversion are known issues nationwide. PharmaSEE removes the shrouds, peels back the curtains and properly records pill-to-patient. Money is tracked by reference number, and drugs are tracked by NDC. Let PharmalytIQ be the detective and alert you when red flags fall outside of standard practices.

340B in every aspect is a compliance program. PharmaSEE will store, report, and certify the supply chain from Pill-to-Patient as being audit ready, audit compliant and transparent.

Pharmalytiq LLC
85 Broad Street, 9th Floor
New York, NY 10004